413 related articles for article (PubMed ID: 29395309)
1. ROR1 and ROR2 play distinct and opposing roles in endometrial cancer.
Henry CE; Llamosas E; Daniels B; Coopes A; Tang K; Ford CE
Gynecol Oncol; 2018 Mar; 148(3):576-584. PubMed ID: 29395309
[TBL] [Abstract][Full Text] [Related]
2. Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion.
Henry C; Llamosas E; Knipprath-Meszaros A; Schoetzau A; Obermann E; Fuenfschilling M; Caduff R; Fink D; Hacker N; Ward R; Heinzelmann-Schwarz V; Ford C
Oncotarget; 2015 Nov; 6(37):40310-26. PubMed ID: 26515598
[TBL] [Abstract][Full Text] [Related]
3. ROR1 is upregulated in endometrial cancer and represents a novel therapeutic target.
Liu D; Gunther K; Enriquez LA; Daniels B; O'Mara TA; Tang K; Spurdle AB; Ford CE
Sci Rep; 2020 Aug; 10(1):13906. PubMed ID: 32807831
[TBL] [Abstract][Full Text] [Related]
4. ROR2 is epigenetically inactivated in the early stages of colorectal neoplasia and is associated with proliferation and migration.
Ma SS; Srivastava S; Llamosas E; Hawkins NJ; Hesson LB; Ward RL; Ford CE
BMC Cancer; 2016 Jul; 16():508. PubMed ID: 27440078
[TBL] [Abstract][Full Text] [Related]
5. miR-379-5p inhibits proliferation and invasion of the endometrial cancer cells by inhibiting expression of ROR1.
Liang M; Chen H; Min J
Acta Biochim Pol; 2021 Jun; 68(4):659-665. PubMed ID: 34115460
[TBL] [Abstract][Full Text] [Related]
6. Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling.
Henry C; Quadir A; Hawkins NJ; Jary E; Llamosas E; Kumar D; Daniels B; Ward RL; Ford CE
J Cancer Res Clin Oncol; 2015 Feb; 141(2):243-54. PubMed ID: 25209439
[TBL] [Abstract][Full Text] [Related]
7. miR-27b-3p suppresses cell proliferation through targeting receptor tyrosine kinase like orphan receptor 1 in gastric cancer.
Tao J; Zhi X; Zhang X; Fu M; Huang H; Fan Y; Guan W; Zou C
J Exp Clin Cancer Res; 2015 Nov; 34():139. PubMed ID: 26576539
[TBL] [Abstract][Full Text] [Related]
8. ROR1 and ROR2 expression in pancreatic cancer.
Liu D; Sharbeen G; Phillips P; ; Ford CE
BMC Cancer; 2021 Nov; 21(1):1199. PubMed ID: 34763666
[TBL] [Abstract][Full Text] [Related]
9. Functional and clinicopathological analysis of loss of MKK4 expression in endometrial cancer.
Ishikawa M; Nakayama K; Rahman MT; Rahman M; Katagiri A; Iida K; Miyazaki K
Oncology; 2010; 79(3-4):238-46. PubMed ID: 21372598
[TBL] [Abstract][Full Text] [Related]
10. Ror family receptor tyrosine kinases regulate the maintenance of neural progenitor cells in the developing neocortex.
Endo M; Doi R; Nishita M; Minami Y
J Cell Sci; 2012 Apr; 125(Pt 8):2017-29. PubMed ID: 22328498
[TBL] [Abstract][Full Text] [Related]
11. Laminin C1 expression by uterine carcinoma cells is associated with tumor progression.
Kashima H; Wu RC; Wang Y; Sinno AK; Miyamoto T; Shiozawa T; Wang TL; Fader AN; Shih IeM
Gynecol Oncol; 2015 Nov; 139(2):338-44. PubMed ID: 26343160
[TBL] [Abstract][Full Text] [Related]
12. MIR-379-5p Expression in Endometrial Cancer and Its Correlation with ROR1 Expression.
Mosaad H; Abdelrahman AE; Abdullatif A; Lashin ME; Ramadan MSH; El-Azony A; Hussien MHS
Asian Pac J Cancer Prev; 2023 Jan; 24(1):239-248. PubMed ID: 36708573
[TBL] [Abstract][Full Text] [Related]
13. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.
Yu J; Chen L; Cui B; Widhopf GF; Shen Z; Wu R; Zhang L; Zhang S; Briggs SP; Kipps TJ
J Clin Invest; 2016 Feb; 126(2):585-98. PubMed ID: 26690702
[TBL] [Abstract][Full Text] [Related]
14. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
[TBL] [Abstract][Full Text] [Related]
15. Silencing ROR1 and ROR2 inhibits invasion and adhesion in an organotypic model of ovarian cancer metastasis.
Henry C; Hacker N; Ford C
Oncotarget; 2017 Dec; 8(68):112727-112738. PubMed ID: 29348860
[TBL] [Abstract][Full Text] [Related]
16. Cellular and molecular mechanisms implicated in the dual role of ROR2 in cancer.
Castro MV; Lopez-Bergami P
Crit Rev Oncol Hematol; 2022 Feb; 170():103595. PubMed ID: 35032666
[TBL] [Abstract][Full Text] [Related]
17. Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer.
Henry CE; Llamosas E; Djordjevic A; Hacker NF; Ford CE
Oncogenesis; 2016 May; 5(5):e226. PubMed ID: 27239958
[TBL] [Abstract][Full Text] [Related]
18. miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer.
Tan H; He Q; Gong G; Wang Y; Li J; Wang J; Zhu D; Wu X
Int J Oncol; 2016 Jan; 48(1):181-90. PubMed ID: 26575700
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal stem cell-derived CXCL16 promotes progression of gastric cancer cells by STAT3-mediated expression of Ror1.
Ikeda T; Nishita M; Hoshi K; Honda T; Kakeji Y; Minami Y
Cancer Sci; 2020 Apr; 111(4):1254-1265. PubMed ID: 32012403
[TBL] [Abstract][Full Text] [Related]
20. Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer.
Henry CE; Emmanuel C; Lambie N; Loo C; Kan B; Kennedy CJ; de Fazio A; Hacker NF; Ford CE
Transl Oncol; 2017 Jun; 10(3):346-356. PubMed ID: 28342318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
